Format
Sort by
Items per page

Send to

Choose Destination

Best matches for cancer cause "hepatitis C":

Hepatitis C virus reactivation in cancer patients in the era of targeted therapies. Yazici O et al. World J Gastroenterol. (2014)

How do persistent infections with hepatitis C virus cause liver cancer? Mitchell JK et al. Curr Opin Virol. (2015)

Natural History of Hepatitis C. Lingala S et al. Gastroenterol Clin North Am. (2015)

Search results

Items: 1 to 20 of 1229

1.

Adaptive mutation F772S-enhanced p7-NS4A cooperation facilitates the assembly and release of hepatitis C virus and is associated with lipid droplet enlargement.

Duan X, Anwar MI, Xu Z, Ma L, Yuan G, Chen Y, Liu X, Xia J, Zhou Y, Li YP.

Emerg Microbes Infect. 2018 Aug 8;7(1):143. doi: 10.1038/s41426-018-0140-z.

2.

[Biological agents intentionally used in Poland based on data from the National Register Of Biological Agents].

Kozajda A.

Med Pr. 2018 Jul 16. pii: 85648. doi: 10.13075/mp.5893.00728. [Epub ahead of print] Polish.

3.

Hepatocellular carcinoma as a leading cause of cancer-related deaths in Japanese type 2 diabetes mellitus patients.

Shima T, Uto H, Ueki K, Kohgo Y, Yasui K, Nakamura N, Nakatou T, Takamura T, Kawata S, Notsumata K, Sakai K, Tateishi R, Okanoue T.

J Gastroenterol. 2018 Jul 13. doi: 10.1007/s00535-018-1494-7. [Epub ahead of print]

PMID:
30006904
4.

Hepatocellular Carcinoma in Malaysia and Its Changing Trend.

Raihan R, Azzeri A, H Shabaruddin F, Mohamed R.

Euroasian J Hepatogastroenterol. 2018 Jan-Jun;8(1):54-56. doi: 10.5005/jp-journals-10018-1259. Epub 2018 May 1. Review.

5.

Microbiome and bile acid profiles in duodenal aspirates from patients with liver cirrhosis: The Microbiome, Microbial Markers and Liver Disease Study.

Jacobs JP, Dong TS, Agopian V, Lagishetty V, Sundaram V, Noureddin M, Ayoub WS, Durazo F, Benhammou J, Enayati P, Elashoff D, Goodman MT, Pisegna J, Hussain S.

Hepatol Res. 2018 Jun 20. doi: 10.1111/hepr.13207. [Epub ahead of print]

PMID:
29923681
6.

An unfortunate failure: multifocal hepatocellular carcinoma in a non-cirrhotic patient with chronic hepatitis C treated with ledipasvir/sofosbuvir.

Soliman MS, Soliman YY, Ahmad Q, Yarlagadda R.

J Community Hosp Intern Med Perspect. 2018 Jun 12;8(3):167-169. doi: 10.1080/20009666.2018.1473702. eCollection 2018.

7.

Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.

Younossi Z, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, Duseja A, Eguchi Y, Wong VW, Negro F, Yilmaz Y, Romero-Gomez M, George J, Ahmed A, Wong R, Younossi I, Ziayee M, Afendy A; Global Nonalcoholic Steatohepatitis Council.

Clin Gastroenterol Hepatol. 2018 Jun 14. pii: S1542-3565(18)30611-6. doi: 10.1016/j.cgh.2018.05.057. [Epub ahead of print]

PMID:
29908364
8.

An Overview of Natural Plant Products in the Treatment of Hepatocellular Carcinoma.

Rawat D, Shrivastava S, Naik RA, Chhonker SK, Mehrotra A, Koiri RK.

Anticancer Agents Med Chem. 2018 Jun 3. doi: 10.2174/1871520618666180604085612. [Epub ahead of print]

PMID:
29866017
9.

Advanced hepatocellular carcinoma: A regional cancer center experience of 48 cases.

Lokesh KN, Chaudhuri T, Lakshmaiah KC, Babu KG, Dasappa L, Jacob LA, Suresh Babu MC, Rudresha AH, Rajeev LK.

Indian J Cancer. 2017 Jul-Sep;54(3):526-529. doi: 10.4103/ijc.IJC_373_17.

10.
11.

A changing etiologic scenario in liver transplantation for hepatocellular carcinoma in a multicenter cohort study from Latin America.

Piñero F, Costa P, Boteon YL, Duque SH, Marciano S, Anders M, Varón A, Zerega A, Poniachik J, Soza A, Padilla Machaca M, Menéndez J, Zapata R, Vilatoba M, Muñoz L, Maraschio M, Podestá LG, McCormack L, Gadano A, Boin ISFF, García P, Silva M; Latin American Liver Research, Education, Awareness Network (LALREAN).

Clin Res Hepatol Gastroenterol. 2018 May 14. pii: S2210-7401(18)30074-3. doi: 10.1016/j.clinre.2018.03.014. [Epub ahead of print]

PMID:
29773419
12.

Mortality trends among people with hepatitis B and C: a population-based linkage study, 1993-2012.

Alavi M, Grebely J, Hajarizadeh B, Amin J, Larney S, Law MG, George J, Degenhardt L, Dore GJ.

BMC Infect Dis. 2018 May 9;18(1):215. doi: 10.1186/s12879-018-3110-0.

13.

Hepatitis A Virus and Hepatitis E Virus: Emerging and Re-Emerging Enterically Transmitted Hepatitis Viruses.

Lemon SM, Walker CM.

Cold Spring Harb Perspect Med. 2018 May 7. pii: a031823. doi: 10.1101/cshperspect.a031823. [Epub ahead of print]

PMID:
29735577
14.

Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation.

Sølund C, Hallager S, Pedersen MS, Fahnøe U, Ernst A, Krarup HB, Røge BT, Christensen PB, Laursen AL, Gerstoft J, Bélard E, Madsen LG, Schønning K, Pedersen AG, Bukh J, Weis N; DANHEP group.

Scand J Gastroenterol. 2018 Jun - Jul;53(7):849-856. doi: 10.1080/00365521.2018.1467963. Epub 2018 May 2.

PMID:
29720023
15.

Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis.

Park H, Jeong D, Nguyen P, Henry L, Hoang J, Kim Y, Sheen E, Nguyen MH.

PLoS One. 2018 Apr 30;13(4):e0196452. doi: 10.1371/journal.pone.0196452. eCollection 2018.

16.

Risk factors for hepatocellular carcinoma by age, sex, and liver disorder status: A prospective cohort study in Korea.

Yi SW, Choi JS, Yi JJ, Lee YH, Han KJ.

Cancer. 2018 Jul 1;124(13):2748-2757. doi: 10.1002/cncr.31406. Epub 2018 Apr 18.

PMID:
29669170
17.

Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication.

Allaire M, Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, DI Martino V, Sutton A, Letouzé E, Audureau E, Roudot-Thoraval F; ANRS CO12 CirVir Group.

Hepatology. 2018 Apr 16. doi: 10.1002/hep.30034. [Epub ahead of print]

PMID:
29663511
18.

Investigation of anti-Hepatitis C virus, sofosbuvir and daclatasvir, in pure form, human plasma and human urine using micellar monolithic HPLC-UV method and application to pharmacokinetic study.

Zidan DW, Hassan WS, Elmasry MS, Shalaby AA.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jun 1;1086:73-81. doi: 10.1016/j.jchromb.2018.04.011. Epub 2018 Apr 7.

PMID:
29660665
19.

[A Case of Hyperammonemia Induced by Chemotherapy with 5-Fluorouracil for Metastatic Colon Cancer].

Tokuyama S, Fukunaga M, Konishi K, Honda S, Yukimoto R, Okamoto A, Saito A, Okada K, Ota H, Yokoyama S, Miki H, Kobayashi K.

Gan To Kagaku Ryoho. 2018 Apr;45(4):743-745. Review. Japanese.

PMID:
29650854
20.

Host-targeting therapies for hepatitis C virus infection: current developments and future applications.

Crouchet E, Wrensch F, Schuster C, Zeisel MB, Baumert TF.

Therap Adv Gastroenterol. 2018 Mar 21;11:1756284818759483. doi: 10.1177/1756284818759483. eCollection 2018. Review.

Supplemental Content

Loading ...
Support Center